首页> 外文期刊>Frontiers in Medicine >Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?
【24h】

Digital Innovation in Medicinal Product Regulatory Submission, Review, and Approvals to Create a Dynamic Regulatory Ecosystem—Are We Ready for a Revolution?

机译:医药产品监管提交的数字创新,审查和批准,创建动态监管生态系统 - 我们为革命准备了吗?

获取原文
           

摘要

The pace of scientific progress over the past several decades within the biological, drug development, and the digital realm has been remarkable. The’omics revolution has enabled a better understanding of the biological basis of disease, unlocking the possibility of new products such as gene and cell therapies which offer novel patient centric solutions. Innovative approaches to clinical trial designs promise greater efficiency, and in recent years, scientific collaborations, and consortia have been developing novel approaches to leverage new sources of evidence such as real-world data, patient experience data, and biomarker data. Alongside this there have been great strides in digital innovation. Cloud computing has become mainstream and the internet of things and blockchain technology have become a reality. These examples of transformation stand in sharp contrast to the current inefficient approach for regulatory submission, review, and approval of medicinal products. This process has not fundamentally changed since the beginning of medicine regulation in the late 1960s. Fortunately, progressive initiatives are emerging that will enrich and streamline regulatory decision making and deliver patient centric therapies, if they are successful in transforming the current transactional construct and harnessing scientific and technological advances. Such a radical transformation will not be simple for both regulatory authorities and company sponsors, nor will progress be linear. We examine the shortcomings of the current system with its entrenched and variable business processes, offer examples of progress as catalysts for change, and make the case for a new cloud based model. To optimize navigation toward this reality we identify implications and regulatory design questions which must be addressed. We conclude that a new model is possible and is slowly emerging through cumulative change initiatives that question, challenge, and redesign best practices, roles, and responsibilities, and that this must be combined with adaptation of behaviors and acquisition of new skills.
机译:在生物学,药物开发中过去几十年的科学进步步伐,数字境界是显着的。 “商学革命”使得更好地了解疾病的生物学基础,解锁了新产品的可能性,如基因和细胞疗法,提供新的患者中心溶液。临床试验设计的创新方法承诺提高效率,近年来,科学合作和联盟一直在开发新颖的方法,利用现实世界数据,患者经历数据和生物标志物数据来利用新的证据来源。除此之外,数字创新迈出了很大进展。云计算已成为主流,事物和区块链技术已成为现实。这些转化的例子与目前的监管提交,审查和批准的目前的低效方法鲜明对比。自20世纪60年代后期医学监管开始以来,此过程并未从根本上改变。幸运的是,如果他们成功地改变当前的交易结构和利用科学和技术进步,则幸运的是,逐步举措将丰富和简化监管决策,并提供患者以患者为中心的疗法提供患者中心疗法。该监管机构和公司赞助商的这种激进的转变将不是简单,也不会进展。我们使用其根深蒂固和可变业务流程检查当前系统的缺点,提供作为变更催化剂的进度的例子,并为新的基于云模型进行案例。为了优化对此现实的导航,我们确定必须解决的影响和监管设计问题。我们得出结论,新模式是可能的,并通过累积变革倡议慢慢出现,这些倡议是质疑,挑战和重新设计的最佳实践,角色和责任,以及这必须与行为的适应相结合并收购新技能。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号